CLINICAL_TRIALS
trial_result
· 2014-08-05
Clinical Trial Update: Fulvestrant in Hormone Refractory Prostate Cancer [Phase 2]
Summary
This Phase 2 trial from Stanford evaluated fulvestrant in hormone-refractory prostate cancer; the study is completed and results were posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Stanford University | Conditions: Prostatic Neoplasms, Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-08-05